Background
==========

Hepatocellular carcinoma (HCC) is one of the most common malignancies and has increasing incidence, which causes millions of cancer-related death globally \[[@b1-medscimonit-21-3144]\]. Due to the low positive rates of diagnosis of HCC, a large proportion of HCC patients lose their opportunity to receive curative-intent therapies, such as resection, radiofrequency ablation, and liver transplantation. The prognosis of patients with advanced HCC with or without prior locoregional treatment is dismal due to lack of effective therapy and the complex nature of liver disease \[[@b2-medscimonit-21-3144]--[@b5-medscimonit-21-3144]\]. However, with the accumulating recognition of underlying mechanisms of HCC, a number of newly developed molecular targeted agents are emerging and changing the situation.

In recent years, much attention has been focused on revealing the molecular factors or pathways that account for tumor development, growth, and metastases. It is now recognized that angiogenesis is crucial for cancer development, survival, and invasion. The process of formation of new blood vessel in the tumor microenvironment has been the target for therapeutic regimens. Angiogenesis is an elegant process consisting of continuous, sequential periods that finally lead to tumor neovascularization. Angiogenesis contributes to the significant growth of many cancers, including HCC, and the vascular endothelial cells are involved in these steps when the dimension of the tumor exceeds 0.5 mm \[[@b6-medscimonit-21-3144],[@b7-medscimonit-21-3144]\]. Vascular endothelial growth factor (VEGF) is a master regulator of angiogenesis in normal and malignant tissues. There are various family members of VEGF and each of them exerts biological functions by binding to different receptors. VEGF plays important roles in prompting proliferation of endothelial cells, thus favoring neovascularization around and within tumor tissues. VEGF participates in several other processes such as recruitment of endothelial cells and activation of receptors related to the proliferation of tumor cells \[[@b8-medscimonit-21-3144],[@b9-medscimonit-21-3144]\]. With regards to the critical roles of VEGF in HCC, VEGF-targeted agents that are effective in the treatment of advanced disease have been developed. Sorafenib is a small molecular tyrosine kinase inhibitor that has been used in the treatment of HCC for years. By blocking the synthesis of important cellular factors (e.g., VEGF) in the regulation of angiogenesis and progression of HCC, sorafenib shows effectiveness in clinical application \[[@b10-medscimonit-21-3144]--[@b13-medscimonit-21-3144]\]. As level of VEGF can be measured in blood samples, several clinical studies questioned whether VEGF could provide sensitive information about HCC response to sorafenib treatment, even adverse events caused by sorafenib. However, the results of these studies do not agree.

In the present meta-analysis, we systematically searched clinical studies related to whether VEGF could predict response of HCC to sorafenib.

Material and Methods
====================

Protocol and registration
-------------------------

The protocol of this review is PRISMA. This study did not have registration information.

Eligibility criteria
--------------------

Patients: advanced HCC patients, with or without prior treatment; Intervention: Sorafenib in combination with other treatment or not; Comparison: low level of VEGF *vs.* high level of VEGF; Outcomes: objective responses, progression-free survival, and overall survival.

Information sources and search
------------------------------

The online electronic databases including PubMed, Embase, the Cochrane Library, and CNKI (China National Knowledge Infrastructure) were included and searched for eligible studies for this meta-analysis (date limit: December 1, 2014). The following terms were used for the systematic search: "hepatocellular carcinoma", "liver cancer", "HCC", "VEGF", "vascular endothelial growth factor", "response", "prognosis" and "sorafenib". For studies without full texts, we contacted the corresponding authors to gain detailed information. We also used Google Scholar to identify relevant studies. The references cited in the reviews were also taken into consideration.

Study selection
---------------

For selecting the eligible articles, we used the following criteria: (1) level of VEGF in the blood sample of patients with HCC was detected by RT-PCR (reverse transcription-polymerase chain reaction) or ELISA (enzyme-linked immunosorbent assay); (2) reporting data on treatment efficacy and survival; (3) only the most recent article investigating the same population published by the same author was included. Two well-trained reviewers were involved in the process of study selection. Any disagreement about inclusion was solved by discussion.

Data extraction and quality assessment
--------------------------------------

Baseline characteristics of each included study, such as title, author, year of publication, journal, numbers of patients, age, sex, intervention, definition of cut-off value, and primary and secondary endpoints, were extracted. If any type of data mentioned above was not available (NA) from the primary study, data were recorded as NA. As most of the included articles were observational studies, quality score or quality-related criteria for inclusion was not applied.

Statistical analysis and synthesis of results
---------------------------------------------

Eligible studies with survival data were included for the synthesis of survival results, and hazard ratio (HR) and its 95% confidence intervals (95% CI) in overall survival (OS) and disease-free survival (DFS) were used for the meta-analysis of survival. If the HR and its 95% CI could not be obtained from the primary study, the methods reported in the study of Parmar et al. was introduced \[[@b14-medscimonit-21-3144]\], or the calculator provided by the RevMan 5.3 was used to gain missing data.

To detect heterogeneity between the included studies, the χ^2^ tests were performed based on the Peto's method \[[@b15-medscimonit-21-3144]\], and inconsistency value (I^2^) was calculated. The fixed-effects model was applied when there was no significant heterogeneity, whereas the random-effects model was used if the heterogeneity between HRs was significant. The pooled effect of VEGF level on predicting response to sorafenib was defined as statistically significant if the p value was less than 0.05. All steps of calculation of meta-analysis were performed by RevMan 5.3 (The Cochrane Collaboration).

Results
=======

Study selection and characteristics
-----------------------------------

After the systematic search, 9 observational studies \[[@b16-medscimonit-21-3144]--[@b24-medscimonit-21-3144]\] involving 1202 patients with HCC were eligible for inclusion ([Figure 1](#f1-medscimonit-21-3144){ref-type="fig"}). The ages of participants had a wide range, from 21 years to 91 years. The publication year ranged from 2011 to 2014. Two studies reported the role of VEGF SNP for predicting response to sorafenib in advanced HCC patients. One study reported data about VEGFR in predicting response to sorafenib. Three trials reported the prognostic value of VEGF level on survival in patients treated with sorafenib. Seven of the 9 studies reported that high level of VEGF was associated with poor efficacy of sorafenib, and the other 2 studies were conference abstracts and did not provide enough information. The detailed characteristics of the included studies are presented in [Table 1](#t1-medscimonit-21-3144){ref-type="table"}.

Results of meta-analysis
------------------------

The cut-off values of defining high level of VEGF were 54.9 pg/ml and 68.6 pg/ml in the studies of Charles and Miyahara, respectively. The pooled results of the OS are shown in [Figure 2](#f2-medscimonit-21-3144){ref-type="fig"}. Overall, the combined HR for the included studies assessing high level of VEGF on OS was 1.85 (95% CI: 1.24--2.77), indicating that high level of VEGF was associated with poor response to sorafenib for HCC. Significant heterogeneity was not observed among the included studies. High level of VEGF had a statistically significant effect on OS in HCC patients treated with sorafenib (*P*=0.003).

The estimated results of the PFS are presented in [Figure 3](#f3-medscimonit-21-3144){ref-type="fig"}. The pooled HR for eligible studies evaluating the prognostic role of high level of VEGF on PFS was 2.09 (95% CI: 1.43--3.05), indicating that high level of VEGF was associated with poor efficacy of sorafenib for HCC. The I^2^ value was 0, indicating that the heterogeneity was not significant between the included studies. High level of VEGF had a statistically significant effect on PFS in HCC patients treated with sorafenib (*P*\<0.01).

We also evaluated the effect of VEGFR2 on predicting efficacy of sorafenib in patients with HCC. The pooled results of the PFS are shown in [Figure 4](#f4-medscimonit-21-3144){ref-type="fig"}. Overall, the combined HR of VEGF on PFS was 1.08 (95% CI: 0.52--2.24), indicating that high level of VEGFR2 failed to reflect the response to sorafenib for HCC. High level of VEGFR2 did not have a statistically significant effect on PFS in HCC patients treated with sorafenib (*P*=0.83).

Only 1 study \[[@b18-medscimonit-21-3144]\] reported data on the effect of VEGF SNPs on incidence of hand-foot skin reaction (HFSR). The pooled results of the VEGF SNP for prediction of HFSR are shown in [Table 2](#t2-medscimonit-21-3144){ref-type="table"}. Overall, VEGF SNPS were associated with high OR for grade 2 or 3 HFSR in HCC patients treated with sorafenib. Mutation of VEGF had a statistically significant effect on incidence of HFSR in HCC patients treated with sorafenib (*P*\<0.05).

One study \[[@b19-medscimonit-21-3144]\] reported VEGF and its genotyping in the prediction of clinical outcome for HCC patients treated with sorafenib; the results showed that VEGF SNPs were significant predictors of PFS and OS ([Table 3](#t3-medscimonit-21-3144){ref-type="table"}).

Discussion
==========

There has been increasing attention on searching for and proving prognostic indicators for HCC patients because these cellular factors guide clinical therapy and monitoring outcomes. To provide as much specific and accurate evidence as possible, it is essential to study certain markers for predicting treatment outcomes using data from clinical trials. In the present study, we examine the prognostic value of different levels of VEGF on predicting outcome of HCC patients who were treated with sorafenib. In this systematic review and meta-analysis, we included and assessed 9 observational studies involving 1202 patients, comparing efficacy of sorafenib in HCC patients with high and low levels of VEGF, aiming to prove the predictive role of VEGF in monitoring efficacy of sorafenib. Pooled estimates showed that high level of VEGF before treatment correlated with good response to sorafenib in HCC.

Besides evaluating the predictive role of VEGF on efficacy and survival in HCC, several published meta-analysis studied the similar value of VEGF in various types of tumors, including lung cancer \[[@b25-medscimonit-21-3144]--[@b29-medscimonit-21-3144]\], gastric cancer \[[@b30-medscimonit-21-3144],[@b31-medscimonit-21-3144]\], colorectal cancer \[[@b32-medscimonit-21-3144],[@b33-medscimonit-21-3144]\], and head and neck squamous cancer \[[@b34-medscimonit-21-3144]\]. These studies together suggested that VEGF plays important roles in development, growth, metastasis, and angiogenesis of tumors, as well as in affecting clinical outcomes in advanced HCC patients. It is now recognized that VEGF is crucial for tumor angiogenesis. VEGF has already been a primary therapeutic target for curing various tumors. Sorafenib is one of the main monoclonal antibodies against generation of several intracellular factors proved to be critical for cancer development and progression, including VEGF. In recent years, sorafenib has been widely used in the treatment of HCC and it exhibited powerful efficacy. However, whether VEGF could be used to predict the response to sorafenib in patients with advanced HCC it is not clear.

Our results showed that VEGF level could be used to predict response to sorafenib in patients with HCC. These data were in accordance with the results of previously published meta-analyses \[[@b35-medscimonit-21-3144]--[@b37-medscimonit-21-3144]\] that reported VEGF was a good indicator of prognosis and outcome, although we mainly focused on systematically reviewing the relationship between VEGF and response to sorafenib in HCC patients. Zhan et al. \[[@b35-medscimonit-21-3144]\] examined the correlation between overexpression of VEGF and the efficacy in HCC patients by searching for relevant articles and analyzing their data. They included 14 studies and the results suggested that high level of VEGF had an unfavorable effect on overall survival, but had no significant impact on disease-free survival. Finally, they concluded that VEGF overexpression indicated a poor prognosis for HCC. Another meta-analysis published in 2009 also examined the relationship between VEGF and clinical outcome in HCC patients \[[@b37-medscimonit-21-3144]\]. The authors performed a meta-analysis to evaluate the use of VEGF as a predictor of survival in patients treated for HCC. The results showed that high VEGF levels predicted poor overall and disease-free survival, indicating that VEGF levels appeared to have obvious predictive ability for evaluating efficacy in HCC and may be useful for defining prognosis in HCC \[[@b37-medscimonit-21-3144]\]. However, these studies did not directly estimate the association between levels of VEGF and efficacy of sorafenib. There were some improvements in our study by only including studies that explored the predictive role of VEGF on response to sorafenib in HCC. The results showed that high level of VEGF after administration of sorafenib was associated with poor response to sorafenib. VEGF may be a useful predictor of the response to sorafenib alone or in combination with other therapies in patients with HCC. Monitoring of VEGF changes after treatment was useful to evaluate the efficacy of sorafenib and to predict the prognosis of advanced HCC.

Three of the 9 studies were performed using patients from hospitals in Asia, and the rest were performed in cohorts from Western populations. This raises the question of whether the results could be skewed, because the prevalence of HCC in Asia is undoubtedly higher than in the rest of the world. By controlling the included studies, we found that the estimated value of VEGF for predicting response to sorafenib was similar. This suggested that the results of this study might be applicable in HCC patients both from Asia and Western.

There are several limitations in the present study. The first is the publication bias. Although there was no significant heterogeneity between included studies, it is worth noting that the number of participants in most of the primary studies are limited, the treatments of HCC patients are sorafenib alone or in combination with other regimens, the samples used for detecting levels of VEGF are different, the detection time of VEGF in different studies varies from 2 weeks to a few months, and the cut-off values for considering high level of VEGF are not consistent among the included studies. These factors influence the overall effect of VEGF in predicting efficacy of sorafenib. The second limitation is that not all of the included studies provided sufficient data for the pooled analysis. A total of 3 articles failed to provide useful information when estimating the role of VEGF for prediction of response to sorafenib. The information about VEGFR was available in only 1 study. Two studies reported VEGF SNPs for predicting clinical outcomes after administration of sorafenib. With regards of these facts, bias within and between studies remains a major concern affecting the results of the meta-analysis. We recommend that the PRISMA \[[@b38-medscimonit-21-3144]\] and the views proposed by McShane et al. \[[@b39-medscimonit-21-3144]\] should be considered for improving the reporting of prognostic studies of tumors; they mainly include blinded assessment of prognostic markers to patient outcome, prospective study design, trial time period, precise outcome definition, provision of candidate variable list, and adequate description and references for assay methods \[[@b37-medscimonit-21-3144]\]. Further studies using the above criteria are needed.

Conclusions
===========

In conclusion, our meta-analysis explored the correlation between prognostic value of VEGF level and efficacy of sorafenib in patients with HCC. As demonstrated in our study, it was concluded that high VEGF level after administration of sorafenib was associated with poor survival and poor clinical efficacy, and no significant heterogeneity was found between studies. In order to strengthen the results, more prospective studies with well-designed, better-standardized detection of VEGF are required to estimate the association between VEGF level and the efficacy of sorafenib in patients with HCC.
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###### 

Baseline characteristics of the included studies.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study              Year   n     Age                      Sex (M/F)   Patients                   Intervention                                     Endpoints                              Samples         Test time
  ------------------ ------ ----- ------------------------ ----------- -------------------------- ------------------------------------------------ -------------------------------------- --------------- ----------------------------------------------------------------------------
  Josep et al.       2012   602   Sorafenib: 64.9±11.2;\   524/78      Advanced, measurable HCC   Sorafenib: 400 mg, bid                           OS, TTP                                Blood           Baseline, 12 weeks after treatment
                                  Control: 66.3±10.2                                                                                                                                                      

  Andrea et al.      2014   44    67.7±10.1                38/6        HCC                        Sorafenib: 800mg/d                               OS, RR                                 Blood           Baseline, 16 weeks after treatment

  Lee et al.         2013   59    57 (37--75)              52/7        HCC                        Sorafenib: 400 mg, bid                           ORR, VEGF                              Blood, tissue   NR

  Scartozzi et al.   2014   148   69 (41--86)              130/18      HCC                        Sorafenib: 400 mg, bid                           VEGF SNPs                              Blood           Baseline, every 3 weeks

  Tsuchiya et al.    2012   47    70±9                     38/9        Advanced, inoperable HCC   Sorafenib                                        Plasma VEGF; RR                        Blood           Baseline, 2 week after, and every month until discontinuation of sorafenib

  Chen et al.        2013   54    45 (21--71)              46/8        Advanced HCC               Sorafenib: 400 mg, bid                           Treatment response, survival and TTP   Tissue          Every 4 weeks

  Miyahara et al.    2013   126   68 (36--91)              105/15      Advanced HCC               Sorafenib: 400/200 mg, bid                       RR, OS, PFS, VEGF                      Blood           NR

  Charles            2011   37    NR                       34/3        Advanced HCC               Sunitinib: 50 mg/day                             ORR                                    Blood           4 weeks

  Tsuchiya et al.    2014   63    70 (40--85)              53/10       Advanced, inoperable HCC   Sorafenib: 800/400/ 200 mg in 28/28/7 patients   OS, RR VEGF                            Blood           Baseline, 1 month after starting sorafenib, and every 3 months thereafter
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

n -- number of patients; M -- male; F -- female; HCC -- hepatocellular carcinoma; OS -- overall survival; TTP -- time to progression; ORR -- objective response rate; NR -- not reported; VEGF -- vascular endothelial growth factor; PFS -- progression free survival; SNPs -- single nucleotide polymorphisms.

###### 

VEGF polymorphisms associated with high-grade (grade 2 or 3) hand-foot skin reactions (n=59).

  SNP            Grade 2 or 3 HFSR   Without grade 2 or 3 HFSR   OR      *P*
  -------------- ------------------- --------------------------- ------- -------
  VEGF 94        40                  19                          13.30   0.005
  VEGF 1991      39                  19                          10.13   0.036
  VEGF IVS3-28   40                  19                          6.28    0.017

VEGF -- vascular endothelial growth factor; HFSR -- hand-foot skin reaction; OR -- odds ratio; SNP -- single nucleotide polymorphism.

###### 

VEGF genetic polymorphisms are associated with different PFS and OS.

  SNPs     Genotype   n     PFS (months)   HR       *P*      OS (months)   HR       *P*
  -------- ---------- ----- -------------- -------- -------- ------------- -------- --------
  VEGF A   CC         108   5.7            1.54     0.038    16.1          2.19     0.0004
  TT+TC    40         3.4   8.6                                                     
  TT+TC    116        6.1   0.64           0.046    14.7     0.57          0.017    
  CC       32         3.0   7.4                                                     
  CC       52         7.6   0.67           0.044    17.9     0.61          0.025    
  AA+AC    96         4.5   12.6                                                    
  CC+CG    87         6.9   1.66           0.0096   17.0     1.91          0.0016   
  GG       61         4.0   9.3                                                     
  VEGF-C   TT+TC      51    10.1           0.57     0.0043   22.0          0.62     0.0334
  CC       97         4.3   13.0                                                    

VEGF -- vascular endothelial growth factor; SNP -- single nucleotide polymorphism; PFS -- progression free survival; HR -- hazard ratio.
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